Literature DB >> 12516988

Using inverse-weighting in cost-effectiveness analysis with censored data.

A R Willan1, D Y Lin, R J Cook, E B Chen.   

Abstract

Due to induced dependent censoring, estimating mean costs and quality-adjusted survival in a cost-effectiveness analysis using standard life-table methods leads to biased results. In this paper we propose methods for estimating the difference in mean costs and the difference in effectiveness, together with their respective variances and covariance in the presence of dependent censoring. We consider the situation in which the measure of effectiveness is either the probability of patients surviving a duration of interest, mean survival time over a duration of interest or mean quality-adjusted survival time over a duration of interest. The method of inverse-weighting is used for censored cost and quality of life data. The methods are illustrated in an example using an incremental net benefit analysis.

Entities:  

Mesh:

Year:  2002        PMID: 12516988     DOI: 10.1191/0962280202sm308ra

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  10 in total

1.  Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer.

Authors:  Niels Neymark; Pilar Lianes; Egbert F Smit; Jan P van Meerbeeck
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Median-based incremental cost-effectiveness ratios with censored data.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2015-05-26       Impact factor: 1.051

3.  EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT.

Authors:  Elizabeth A Handorf; Justin E Bekelman; Daniel F Heitjan; Nandita Mitra
Journal:  Ann Appl Stat       Date:  2013       Impact factor: 2.083

4.  Nonparametric inference for time-dependent incremental cost-effectiveness ratios.

Authors:  Laura M Yee; Kwun Chuen Gary Chan
Journal:  Stat Med       Date:  2015-07-27       Impact factor: 2.373

5.  The cost-effectiveness of the decision to hospitalize nursing home residents with advanced dementia.

Authors:  Keith S Goldfeld; Mary Beth Hamel; Susan L Mitchell
Journal:  J Pain Symptom Manage       Date:  2013-04-06       Impact factor: 3.612

6.  Cost-effectiveness of initial stress cardiovascular MR, stress SPECT or stress echocardiography as a gate-keeper test, compared with upfront invasive coronary angiography in the investigation and management of patients with stable chest pain: mid-term outcomes from the CECaT randomised controlled trial.

Authors:  Howard Thom; Nicholas E J West; Vikki Hughes; Matthew Dyer; Martin Buxton; Linda D Sharples; Christopher H Jackson; Andrew M Crean
Journal:  BMJ Open       Date:  2014-02-07       Impact factor: 2.692

7.  Cost effectiveness analysis of larval therapy for leg ulcers.

Authors:  Marta O Soares; Cynthia P Iglesias; J Martin Bland; Nicky Cullum; Jo C Dumville; E Andrea Nelson; David J Torgerson; Gill Worthy
Journal:  BMJ       Date:  2009-03-19

8.  Cost-effectiveness of compression technologies for evidence-informed leg ulcer care: results from the Canadian Bandaging Trial.

Authors:  Ba' Pham; Margaret B Harrison; Maggie H Chen; Meg E Carley
Journal:  BMC Health Serv Res       Date:  2012-10-02       Impact factor: 2.655

9.  Clinical and cost-effectiveness analysis of an open label, single-centre, randomised trial of spinal cord stimulation (SCS) versus percutaneous myocardial laser revascularisation (PMR) in patients with refractory angina pectoris: The SPiRiT trial.

Authors:  M T Dyer; K A Goldsmith; S N Khan; L D Sharples; C Freeman; I Hardy; M J Buxton; P M Schofield
Journal:  Trials       Date:  2008-06-30       Impact factor: 2.279

10.  Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT.

Authors:  Shabbir M H Alibhai; Paul Ritvo; Daniel Santa Mina; Catherine Sabiston; Murray Krahn; George Tomlinson; Andrew Matthew; Himu Lukka; Padraig Warde; Sara Durbano; Meagan O'Neill; S Nicole Culos-Reed
Journal:  BMC Cancer       Date:  2018-10-23       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.